EnBiotix, Inc.
Engineered bacteriophages delivering genetic payloads to bacteria to enhance antibiotic efficacy and combat biofilm infections
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Latest Form D
- $3.5M, Apr 2022
- Total capital
- $6.9M
- Federal grants
- $264K
- 1 award · 2016
- Rank in peer group#164 of 392
- Private capital raised
- $6.6M
- 2 Form D · last Apr 2022
- 55 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 8 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$3.5M
- Private capital raisedForm D · SEC · 1st filing$3.1M
- Federal grantHealth and Human S · Phase I · Engineered bacteriophage as a platform to deliver nucleic acid based therapeutics to bacteria to disperse biofilms in implant-associated infections such as prosthetic joint infections$264K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
39months
from EnBiotix, Inc.’s first federal award to its first private round.
- First federal award · Jul 2016
- Health and Human S · $264K
- First Form D · Sep 2019
- $3.1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#164 · top 42%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Daniel D. HartmanDirectorNamed in SEC Form D filings
- Dennis D. AusielloDirectorNamed in SEC Form D filings
- Jeffrey D. WagerExecutive Officer, DirectorNamed in SEC Form D filings
- Roberto D. GuttmannDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 8- PendingAminoglycoside Potentiation For Treatment Of Pulmonary Bacterial InfectionUSPTOApplication 18135907
- PendingAminoglycoside Potentiation For Treatment Of Pulmonary Bacterial InfectionUSPTOApplication 16467665
- PendingBacteriophage For Treating Staphylococcus InfectionsUSPTOApplication 15746663
Show all 8 patent records
- Aminoglycoside Potentiation For Treatment Of Pulmonary Bacterial InfectionAug 10, 2023 · Application 18135907Pending
- Aminoglycoside Potentiation For Treatment Of Pulmonary Bacterial InfectionMar 5, 2020 · Application 16467665Pending
- Bacteriophage For Treating Staphylococcus InfectionsJun 6, 2019 · Application 15746663Pending
- Aminoglycoside Potentiation For Treatment Of Pulmonary Bacterial InfectionApplication PCTUS2017065291Pending
- Bacteriophages For Neutralizing Toxins And Methods Of Use ThereofApplication PCTUS2017047503Pending
- Bacteriophage For Treating Staphylococcus InfectionsApplication PCTUS2016043815Pending
- Aminoglycoside Potentiation For Treatment Of Nontuberculous Mycobacterial Lung DiseaseApplication 62860990Pending
- Bacteriophage Having Modified Recognition Baseplate Protein Structural DomainsApplication PCTUS2017068893Pending
Related companies, and why
- Mitokinin, Inc.Similar federal contract value in Biotech · null in contracts
- NEMAGEN DISCOVERIES INCSimilar federal contract value in Biotech · null in contracts
- Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
- MIMIVAX, LLCSimilar federal contract value in Biotech · null in contracts
- T3D Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Novosteo Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .